Jason N. Valent

Jason N. Valent

Hematology | Oncology

9500 Euclid Avenue
Cleveland, OH 44195

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 86 publications

Limited duration of dexamethasone in newly diagnosed AL amyloidosis: impact on response, toxicity, and survival.

Limited duration of dexamethasone in newly diagnosed AL amyloidosis: impact on response, toxicity, and survival.

Journal: Annals of medicine

Published: August 07, 2026

The first case of Teclistamab interference with serum electrophoresis and immunofixation.

The first case of Teclistamab interference with serum electrophoresis and immunofixation.

Journal: Clinical chemistry and laboratory medicine

Published: May 12, 2026

Spontaneous Acute Left-Sided Abdominal Pain in a Patient With AL Amyloidosis.

Spontaneous Acute Left-Sided Abdominal Pain in a Patient With AL Amyloidosis.

Journal: EJHaem

Published: April 09, 2026

Response kinetics and depth of response after idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Response kinetics and depth of response after idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Journal: Blood cancer journal

Published: April 03, 2026

BIO26-048: A Meta-Analytic Evaluation of Efficacy and Safety Between Ide-cel and Cilta-cel in Relapsed/Refractory Multiple Myeloma Based on Clinical Trial and Real-World Data.

BIO26-048: A Meta-Analytic Evaluation of Efficacy and Safety Between Ide-cel and Cilta-cel in Relapsed/Refractory Multiple Myeloma Based on Clinical Trial and Real-World Data.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 31, 2026

Smoldering Multiple Myeloma: Early Intervention or Structured Surveillance? A Comprehensive Review of Evidence for and Against Early Therapy.

Smoldering Multiple Myeloma: Early Intervention or Structured Surveillance? A Comprehensive Review of Evidence for and Against Early Therapy.

Journal: Cancers

Published: March 18, 2026

Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology.

Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: February 11, 2026

Multiple Myeloma Screening Education: A Community-Based Health Literacy Intervention.

Multiple Myeloma Screening Education: A Community-Based Health Literacy Intervention.

Journal: Cancer research communications

Published: January 20, 2026

Triplet or Quadruplet Regimen Utilization and Overall Survival in Patients Diagnosed With Multiple Myeloma Between 2017 and 2023.

Triplet or Quadruplet Regimen Utilization and Overall Survival in Patients Diagnosed With Multiple Myeloma Between 2017 and 2023.

Journal: EJHaem

Published: January 19, 2026

Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.

Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 10, 2025

Estimated Stressed Blood Volume in Patients With Cardiac Amyloidosis.

Estimated Stressed Blood Volume in Patients With Cardiac Amyloidosis.

Journal: The American journal of cardiology

Published: November 27, 2025

Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort.

Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort.

Journal: Blood cancer journal

Published: November 03, 2025

Showing 1-12 of 86

Last Updated: 09/26/2026